Trial · NCT04070326
Adverse events112
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 112
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Diplopia | Eye disorders | Lanadelumab 150 mg, q4wks | 0 | 11 | 0 |
| other | Diplopia | Eye disorders | Lanadelumab 150 mg, q2wks | 1 | 18 | 1 |
| other | Eye inflammation | Eye disorders | Lanadelumab 150 mg, q4wks | 0 | 11 | 0 |
| other | Eye inflammation | Eye disorders | Lanadelumab 150 mg, q2wks | 1 | 18 | 1 |
| other | Abdominal pain | Gastrointestinal disorders | Lanadelumab 150 mg, q4wks | 1 | 11 | 1 |
| other | Abdominal pain | Gastrointestinal disorders | Lanadelumab 150 mg, q2wks | 2 | 18 | 3 |
| other | Tooth loss | Gastrointestinal disorders | Lanadelumab 150 mg, q4wks | 0 | 11 | 0 |
| other | Tooth loss | Gastrointestinal disorders | Lanadelumab 150 mg, q2wks | 1 | 18 | 2 |
| other | Abdominal pain upper | Gastrointestinal disorders | Lanadelumab 150 mg, q4wks | 0 | 11 | 0 |
| other | Abdominal pain upper | Gastrointestinal disorders | Lanadelumab 150 mg, q2wks | 1 | 18 | 1 |
| other | Toothache | Gastrointestinal disorders | Lanadelumab 150 mg, q4wks | 0 | 11 | 0 |
| other | Toothache | Gastrointestinal disorders | Lanadelumab 150 mg, q2wks | 1 | 18 | 1 |
| other | Injection site pain | General disorders | Lanadelumab 150 mg, q4wks | 2 | 11 | 12 |
| other | Injection site pain | General disorders | Lanadelumab 150 mg, q2wks | 6 | 18 | 76 |
| other | Injection site erythema | General disorders | Lanadelumab 150 mg, q4wks | 2 | 11 | 8 |
| other | Injection site erythema | General disorders | Lanadelumab 150 mg, q2wks | 2 | 18 | 21 |
| other | Injection site swelling | General disorders | Lanadelumab 150 mg, q4wks | 0 | 11 | 0 |
| other | Injection site swelling | General disorders | Lanadelumab 150 mg, q2wks | 1 | 18 | 3 |
| other | Pyrexia | General disorders | Lanadelumab 150 mg, q4wks | 0 | 11 | 0 |
| other | Pyrexia | General disorders | Lanadelumab 150 mg, q2wks | 2 | 18 | 2 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT04070326/events